文献速递前列腺癌

雄激素受体变异驱动的前列腺癌II:临床研究进展

Androgen receptor variant-driven prostate cancer II: advances in clinical investigation.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2020-02-24

约10-30%的mCRPC男性通过两种经验证CTC检测AR-V7阳性,对AR靶向治疗反应差但可能保留化疗敏感性。本文系统综述2016年以来文献,讨论检测的临床意义及AR-V7阳性患者管理策略,并探讨变异是乘客还是驱动因素。

要点

  • 约10-30%的mCRPC男性AR-V7阳性,对AR靶向治疗反应差且生存期短。
  • AdnaTest mRNA或Epic核蛋白CTC检测是首批经验证液体活检,可指导治疗决策。
  • AR-V7阳性患者可能保留化疗敏感性,但需要超越紫杉类的新策略。

核心结论

  • CTC AR-V7检测(AdnaTest mRNA或Epic核蛋白法)是首批经验证液体活检,可 informing mCRPC治疗决策,尤其一线AR治疗失败后。
  • AR-V7阳性患者对AR靶向治疗反应概率低,无进展生存和总生存短。
  • AR变异非孤立存在,mCRPC基因组和表型异质复杂,多重耐药机制可能共存。

研究设计与样本

  • 系统综述文献,覆盖2016年综述以来关于mCRPC雄激素受体变异、结局及治疗方法的更新。

主要发现

  • 约10-30%的mCRPC男性通过两种经验证CTC检测AR-V7阳性。
  • AR-V7阳性患者对AR靶向治疗反应概率低,多变量分析显示无进展生存和总生存短。
  • AR变异存在于复杂异质且演变的mCRPC基因组和表型背景中,患者无论AR-V7状态均可能存在多重耐药机制。

临床怎么用

  • 对mCRPC患者,尤其一线AR靶向治疗失败后,可考虑CTC AR-V7检测以辅助治疗决策。
  • AR-V7阳性患者可能对化疗保留敏感性,应考虑化疗等替代策略。
  • 需要开发更广泛的耐药检测和超越紫杉类的有效治疗策略。

局限性

  • AR-V7检测仅识别部分耐药患者,多重耐药机制可能共存,需更广泛耐药检测。
  • 需要有效治疗策略超越紫杉类以针对AR变异的驱动作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Approximately 10-30% of men with mCRPC will test positive for AR-V7 using one of two analytically and clinically validated circulating tumor cell (CTC)-based assays. These men have poor outcomes with approved AR-targeting therapies but may retain sensitivity to chemotherapy. Here, we discuss the clinical implications of testing and strategies that may benefit AR splice variant (AR-V)-positive men and discuss whether such variants are passengers or drivers of aggressive clinical behavior. METHODS: We conducted a systemic review of the literature, covering updates since our 2016 review on androgen receptor variants in mCRPC, outcomes, and existing and novel approaches to therapy. We provide an expert opinion about management strategies for AR-V7-positive men and key unanswered research questions. RESULTS: AR-V7-positive men, defined by Epic nuclear protein detection or the modified AdnaTest mRNA detection in CTCs, identify a subset of men with mCRPC that have a low probability of response to AR-targeting therapy with short progression-free and overall survival in multivariable analyses. AR-variants do not exist in isolation, but rather in the context of a complex, heterogeneous, and evolving mCRPC genome and phenotype as well as patient-specific clinical heterogeneity, and multiple mechanisms of resistance likely exist in patients regardless of AR-V7 detection. Efforts to develop broader resistance assays are needed, and effective treatment strategies beyond taxanes are needed to address the causal driver role of AR-variants and to benefit patients with AR-V-expressing prostate cancer. CONCLUSIONS: CTC AR-V7 detection using the AdnaTest mRNA or Epic nuclear protein assays represents the first analytically and prospective clinically validated liquid biopsy assays that may inform treatment decisions in men with mCRPC, particularly after failure of first-line AR-therapy. The importance of AR-variants is likely to increase with the earlier use of AR-targeting strategies in other settings, and novel interventions for these men are needed.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Brown LC, Lu C, Antonarakis ES, et al. Androgen receptor variant-driven prostate cancer II: advances in clinical investigation. Prostate Cancer Prostatic Dis. 2020. PMID: 32094489. doi:10.1038/s41391-020-0215-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。